In adults with class II/III obesity without type 2 diabetes, open-label liraglutide 3.0 mg reduced body weight by 5.8% versus placebo at week 26.
In plain wordsIn adults with severe obesity and no diabetes, liraglutide lowered body weight more than placebo after 26 weeks.
- Peptide
- Liraglutide
- Outcome
- DecreasePlacebo-subtracted body weight change at week 26
- Study
n: not reported in source
- Comparator
- Placebo
- Analysis
- Primary
- Outcome group
- Body weight · Metabolic and weight
- Studied dose
- 3.0 mg · 26 weeksAs given in this study (human).
Measurements
- Placebo-subtracted body weight change
- −5.8%
- liraglutide 3.0 mg, week 26
Source sentences
At week 26, placebo-subtracted body weight changes (adjusted for multiplicity) were -6.8%, -8.1% and -10.0% for the JNJ-64565111 5.0 mg, 7.4 mg and 10.0 mg groups, respectively, and -5.8% for the liraglutide group.
1 context sentence(design, population, supporting numbers)
participants aged 18 to 70 years with a body mass index of 35 to 50 kg/m2 and stable weight were randomly assigned in a 1:1:2:2:2 ratio to blinded treatment with placebo; JNJ-64565111 (5.0, 7.4 or 10.0 mg, each with no dose escalation), or open-label liraglutide 3.0 mg